Endo 607 (Carbidopa and levodopa 25 mg / 250 mg)
Pill imprint Endo 607 has been identified as Carbidopa and levodopa 25 mg / 250 mg.
Carbidopa/levodopa is used in the treatment of parkinson's disease; restless legs syndrome; neuroleptic malignant syndrome; gtp-ch deficiency and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 25 mg / 250 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- Endo 607
- Strength:
- 25 mg / 250 mg
- Color:
- Blue
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- Dopaminergic antiparkinsonism agents
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Endo Pharmaceuticals Inc.
- National Drug Code (NDC):
- 60951-0607
More about carbidopa/levodopa
Consumer resources
- Carbidopa and levodopa
- Carbidopa and levodopa extended-release capsules
- Carbidopa and levodopa orally disintegrating tablets
- Carbidopa and levodopa suspension
- Carbidopa and levodopa sustained-release tablets
- More (6) »
- Other brands: Sinemet, Rytary, Sinemet CR, Parcopa, More (1) »
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
